Download PDF

1. Company Snapshot

1.a. Company Description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases.The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors.


The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19.The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression.It has a license agreement with Caris Life Sciences.


Xencor, Inc.was incorporated in 1997 and is headquartered in Monrovia, California.

Show Full description

1.b. Last Insights on XNCR

Xencor's recent performance was negatively impacted by a Q4 loss of $0.62 per share, although this was better than the Zacks Consensus Estimate of a loss of $0.83. The company's revenue topped estimates, but the earnings miss and declining pipeline exposure weighed on the stock. Xencor's decision to rebalance its pipeline by focusing on XmAb drug candidates that leverage its protein engineering strengths may have contributed to the negative sentiment. Additionally, the company's shift away from biologics may have raised concerns about its growth prospects.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Y Intercept Hong Kong Ltd Purchases 46,140 Shares of Xencor, Inc. $XNCR

Nov -06

Source: defenseworld.net

Card image cap

Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates

Nov -05

Source: zacks.com

Card image cap

Xencor (XNCR) Projected to Post Earnings on Wednesday

Nov -04

Source: defenseworld.net

Card image cap

Xencor, Inc. (XNCR) Discusses Initial Phase I Dose Escalation Results for XmAb819 in Advanced Clear Cell Renal Cell Carcinoma Transcript

Oct -24

Source: seekingalpha.com

Card image cap

Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Oct -21

Source: businesswire.com

Card image cap

Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight

Sep -29

Source: globenewswire.com

Card image cap

Xencor: Bispecific Antibody Program Takes Shape With Q4 Data Release

Sep -19

Source: seekingalpha.com

Card image cap

Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

Aug -06

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.40%)

6. Segments

Monoclonal Bispecific Antibody and Cytokine Therapeutics

Expected Growth: 12.4%

Xencor's Monoclonal Bispecific Antibody and Cytokine Therapeutics growth is driven by increasing adoption in oncology and autoimmune diseases, strong clinical trial results, and partnerships with pharma companies. The bispecific antibody platform's potential to enhance efficacy and reduce toxicity also contributes to the 12.4% growth.

7. Detailed Products

XmAb Bispecific Antibodies

XmAb bispecific antibodies are designed to bind to two different targets simultaneously, allowing for more precise and effective targeting of disease-causing cells.

XmAb T Cell Bispecific Antibodies

XmAb T cell bispecific antibodies are designed to redirect T cells to target and kill cancer cells, enhancing the body's natural immune response.

XmAb Cytokine Bispecific Antibodies

XmAb cytokine bispecific antibodies are designed to target specific cytokines, which are proteins that regulate the immune response, to modulate the immune system.

XmAb IL15 Bispecific Antibodies

XmAb IL15 bispecific antibodies are designed to target IL-15, a cytokine that plays a key role in the immune response, to enhance the body's natural immune response.

8. Xencor, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Xencor, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for cancer and autoimmune diseases.

Bargaining Power Of Customers

Xencor, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative suppliers.

Bargaining Power Of Suppliers

Xencor, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services.

Threat Of New Entrants

Xencor, Inc. has a high threat of new entrants due to the growing demand for cancer and autoimmune disease treatments and the availability of funding for biotech startups.

Intensity Of Rivalry

Xencor, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 3.52%
Debt Cost 3.95%
Equity Weight 96.48%
Equity Cost 7.76%
WACC 7.63%
Leverage 3.65%

11. Quality Control: Xencor, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Nektar

A-Score: 4.5/10

Value: 8.0

Growth: 4.2

Quality: 4.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Werewolf Therapeutics

A-Score: 3.9/10

Value: 7.4

Growth: 4.4

Quality: 5.8

Yield: 0.0

Momentum: 5.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
HOOKIPA Pharma

A-Score: 3.6/10

Value: 9.2

Growth: 5.8

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Absci

A-Score: 2.8/10

Value: 6.6

Growth: 2.7

Quality: 3.8

Yield: 0.0

Momentum: 2.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Palisade Bio

A-Score: 2.7/10

Value: 6.4

Growth: 5.7

Quality: 3.5

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Xencor

A-Score: 2.5/10

Value: 7.2

Growth: 1.1

Quality: 4.4

Yield: 0.0

Momentum: 0.0

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

17.3$

Current Price

17.3$

Potential

-0.00%

Expected Cash-Flows